

Certificate of Analysis

Name: SARS-CoV-2 Purified Viral Lysate

Product Code: NAT41605-100 / NAT41605-500

Batch #:

Date of Manufacture:

Product Description: This virus was isolated from a patient with a respiratory illness who had returned from travel to the affected region of China and developed COVID-19 in January 2020 in Washington, USA.

Sequence Strain: SARS-Related Coronavirus 2 (SARS-CoV-2, Isolate: USA-WA1/2020)

NCBI GenBank Accession No.: MN985325

Purification: The virus is purified using sucrose density gradient ultracentrifugation, disrupted in the presence of 0.5% Triton X-100 non-ionic detergent/0.6 M KCl, and heat inactivated.

Inactivation: Viral inactivation is verified by the absence of viral growth in tissue culture-based infectivity assays. Endpoint dilution assays are used to evaluate the pre-inactivation TCID₅₀ titer and the lysate samples. Three independent lysate samples are inoculated into VeroE6 cells (n=4) and incubated for 7 days at 37°C. The inoculated cell cultures are observed for signs of cytopathic effects (CPE). All lysate samples must demonstrate no CPE to verify inactivation of the product.

Health and Safety: This product is potentially biohazardous. It should be handled with appropriate safety precautions for biological materials. Local biosafety procedures should be maintained at all times.

Amount: 0.1mg / 0.5mg

Concentration: ≥ 0.5 mg/mL by BCA Protein Assay

Presentation: Frozen lysate

Usage Guidelines

Short Term Storage: -80°C

Long Term Storage: -80°C



General: Repetitive freezing and thawing is not recommended (aliquot material if necessary). To avoid cross-contamination, use separate pipette tips for all reagents.

X

QC

X

QA

Products are for Research Use or for Further Manufacturing Use only. Not for Diagnostic or Therapeutic Use.

SARS-CoV-2 is a Biosafety Level 3 microorganism when infectious. When inactivated it must be used within a Biological Safety Level 2 facility or biosafety cabinet. Please consult your institution's regulations regarding the use of this product.

For a detailed discussion on biological safety see;

1. [The Genetically Modified Organisms \(Contained Use\) Regulations 2014](#), [The SACGM Compendium of Guidance](#), and [Control of Substances Hazardous to Health \(Sixth Edition\)](#), published by the UK Health and Safety Executive (HSE).
2. The 5th edition of Biosafety in Microbiological and Biomedical Laboratories (BMBL), published by the CDC at <http://www.cdc.gov/biosafety/publications/bmb15/index.htm>.